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Although metastasis-associated protein 1 (MTA1) has re-
cently been shown as a DNA damage responsive protein, the
underlying mechanism for its role in DNA double-strand break
(DSB) repair remains unknown. Here, we show thatMTA1 con-
trols p53 stability through inhibiting its ubiquitination by E3
ubiquitin ligases mouse double minute 2 (Mdm2) and constitu-
tive photomorphogenic protein 1 (COP1). The underlying
mechanisms involve the ability ofMTA1 to compete with COP1
to bind to p53 and/or to destabilize COP1 and Mdm2. Conse-
quently, MTA1 regulates the p53-dependent transcription of
p53R2, a direct p53 target gene for supplying nucleotides to
repair damaged DNA. Depletion of MTA1 impairs p53-depen-
dent p53R2 transcription and compromises DNA repair. Inter-
estingly, these events could be reversed by MTA1 reintroduc-
tion, indicating that MTA1 interjects into the p53-dependent
DNA repair. Given the fact thatMTA1 is widely up-regulated in
human cancers, these findings in conjunction with our earlier
finding of a crucial role ofMTA1 inDSB repair suggest an inher-
ent role of the MTA1-p53-p53R2 pathway in DNA damage
response in cancer cells.
The p53 tumor suppressor is a central component of cel-
lular mechanisms that respond to DNA damage signals to
preserve genomic integrity (1, 2). Under physiological con-
ditions, p53 is tightly regulated and normally maintained at
low levels by the action of several RING finger E3 ubiquitin
ligases, including constitutive photomorphogenic protein 1
(COP1) (3), mouse double minute 2 (Mdm2) (4, 5), and p53-
induced protein with a RING H2 domain (Pirh2) (6). All of
these ligases are transcriptionally stimulated by the p53 pro-
tein and in turn, target p53 for the ubiquitin-dependent pro-
teolysis, thereby creating tight negative feedback loops for
controlling p53 protein stability (7). Accordingly, disruption
of these autoregulatory feedback loops is a pivotal event for
the activation of p53 in response to various genotoxic
stresses (8, 9). Following DNA damage, p53 protein is stabi-
lized and activated through post-translational modifica-
tions, resulting in a controlled activation of a series of down-
stream target genes that mediate its functions (10–12). In
addition to its important functions in cell cycle arrest and
apoptosis (2, 12), the p53 protein plays a critical role in reg-
ulating DNA repair caused by various genotoxic stresses
(13–17). Loss of p53 function leads to decreased repair of
damaged DNA and is reflected by increased sensitivity to
DNA damage agents. Therefore, blocking the p53-induced
DNA repair could prove to be an efficient approach to en-
hance the efficacy of DNA-damaging agents (18).
Recently, numerous potential mechanisms have been de-
scribed as to how p53 functions to regulate DNA repair. p53
directly associates with TFIIH, a nucleotide excision repair
component (19) and transactivates genes implicated in DNA
repair, such as p53R2, a newly identified subunit of ribonucle-
otide reductase (20, 21). The ability of p53R2 to supply nucleo-
tides for repairing DNA damage requires the presence of a
functional p53 protein, and inactivation of p53 directly inter-
feres with the transcription of p53R2 in response to DNA dam-
age (20). In function, inactivation of p53R2 impairs DNA repair
and sensitizes several types of cancer cells to DNA-damaging
anticancer agents or to ionizing radiation (IR) (20, 22, 23). Thus,
it is quite clear that p53 protein plays a critical role in regulating
DNA repair caused by various genotoxic stresses through tran-
scriptional induction of p53R2.
Themetastasis-associated protein (MTA)2 family represents
an emerging family of ubiquitously expressed chromatin mod-
ifiers, which have an integral role in the nucleosome remodel-
ing and histone-deacetylase (NuRD) complexes (24, 25). The
members of MTA family have been shown to interact and
deacetylate non-histone proteins. For example, the MTA2-
histone deacetylase 1 (HDAC1) complex has been shown to
deacetylate p53 and represses the ability of p53 to stimulate the
transcription of genes important in growth and apoptosis (26).
However, MTA family members exist in distinct NuRD com-
plexes, and functional redundancy is lacking amongMTA fam-
ily members (27). MTA1 is highly up-regulated in a variety of
human cancers with metastatic potential (28–30). Recent data
suggest that MTA1 may interact with p53 (27, 31), but there
are conflicting reports about its effect on p53 levels with no
mechanistic insights (32, 33), and thus, the effect of MTA1
on p53 expression and involvement of MTA1 in p53-de-
pendent DNA damage response remain unclear.
* This work was supported, in whole or in part, by National Institutes of Health
Grants CA98823 and CA98823-S1 (to R. K.).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S7 and Table S1.
1 To whom correspondence should be addressed. E-mail: bcmrxk@gwumc.
edu.
2 The abbreviations used are: MTA, metastasis-associated protein; DSB,
double-strand break; HA, hemagglutinin; GST, glutathione S-transfer-
ase; qPCR, quantitative PCR; MEF, mouse embryonic fibroblast; IP,
immunoprecipitation.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 50, pp. 34545–34552, December 11, 2009
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
DECEMBER 11, 2009 • VOLUME 284 • NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34545
Recent data from our laboratory suggest that MTA1 is a
DNA damage responsive protein as it is stabilized in response
to IR, and facilitates DNA double-strand break (DSB) repair
(34), but the underlying mechanism remains unknown. Here,
using a variety of genetic, biochemical, and molecular ap-
proaches, we show that MTA1 is a direct stabilizer of the p53
protein by inhibiting its ubiquitination by E3 ligases, and there-
fore regulates p53-dependent function in DNA repair. These
findings in conjunction with our earlier finding of a crucial role
of MTA1 in DSB repair suggest that MTA1 is a potential ther-
apeutic target that could be used to enhance the effectiveness of
IR or DNA-damaging anticancer agents in cancer cells by tar-
geting MTA1 expression.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—Human U2OS, MCF-7, H1299,
and HEK293 cells were obtained from the American Type Cul-
ture Collection (Manassas, VA). p53//Mdm2/ double
knock-out mouse embryonic fibroblasts (MEFs) were kindly
provided by Dr. G. Lozano (M. D. Anderson Cancer Center,
Houston, TX).MTA1/ andMTA1/MEFswere generated
in our laboratory from embryos at day 9 of development by
using a standard protocol (35). Stable clones of MTA1/
MEFs stably expressing V5-MTA1, and of MCF-7/pcDNA3.1
andMCF-7/T7-MTA1 have been described previously (34, 36).
All cell lines were grown in the recommended medium by the
providers supplemented with 10% fetal bovine serum and 1
antibiotic-antimycotic solution in a humidified 5% CO2 at
37 °C. Cell culture medium and additives were obtained from
Invitrogen (Carlsbad, CA) if not otherwise stated.
Expression Vectors, Recombinant Proteins, siRNA, and
Transfections—The following mammalian expression vectors
were used in this study: pCMV-p53 (Duen-Hwa Yan, M. D.
Anderson Cancer Center, Houston, TX), hemagglutinin (HA)-
tagged ubiquitin (HA-Ub) (Peter B. Zhou, UT Medical School,
Galveston, TX), pCMV-Mdm2 (Yanping Zhang, University of
North Carolina at Chapel Hill, NC), pcDNA3-Flag-Mdm2
(Xiongbin Lu, University of South Carolina), glutathione S-
transferase (GST)-Mdm2 deletion constructs (Mark K Saville,
University of Dundee, UK), and GST-p53 deletion constructs
(Arnold J. Levine, University of Medicine and Dentistry of
New Jersey, Rutger, NJ). Full-length COP1 cDNA was sub-
cloned into pcDNA3.1-T7 vector (Invitrogen) to generate T7-
taggedCOP1.Myc-taggedMTA1 (Myc-MTA1) andV5-tagged
MTA1 (V5-MTA1) were generated by polymerase chain reac-
tion (PCR)-based subcloning of full-length MTA1 cDNA into
pCMV-Myc vector (Clontech, Mountain View, CA) and
pcDNA6/V5-His C vector (Invitrogen), respectively. All GST
recombinant proteins were expressed in Escherichia coli strain
BL21 (DE3) (Stratagene, La Jolla, CA) and subsequently puri-
fied using the glutathione-Sepharose 4B batch method (Amer-
sham Biosciences). In vitro transcription/translation of recom-
binant protein was performed using the TNT Quickcoupled
Transcription/Translation system (Promega, Madison, WI).
Plasmid transfections were carried out using FuGENE HD
TransfectionReagent (RocheApplied Science) according to the
manufacturer’s instructions. Cells were cotransfected with the
indicated vectors, and the total amounts of DNA were equal-
izedwith corresponding empty vectors. Specific siRNAs target-
ing human MTA1 (Cat. M-004127-02) and non-targeting
control siRNAs (Cat. D-001210-01) were obtained from Dhar-
macon (Lafayette, CO). The transfection of siRNA was per-
formed twice at 24-h intervals with Oligofectamine Reagent
(Invitrogen) according to the manufacturer’s protocol. Cells
were collected after 36 h of transfection for further analyses.
Antibodies and Reagents—Sources of antibodies were as
follows: rabbit polyclonal anti-p53 (FL393) (Santa Cruz Bio-
technology, Santa Cruz, CA), anti-Flag (Sigma-Aldrich), anti-
MTA1, and anti-COP1 (Bethyl Laboratories, Montgomery,
TX), goat polyclonal anti-MTA1 (C17) (SantaCruzBiotechnol-
ogy), and rat monoclonal anti-HA (3F10) (Roche Applied Sci-
ence). Mouse monoclonal anti-p53 (DO-1) (Santa Cruz Bio-
technology), anti-Myc (9E10.3) (Neomarkers, Fremont, CA),
anti-ubiquitin (P4D1) (Cell Signaling Technology, Danvers,
MA), anti-Mdm2 (Ab-1 and Ab-4) (Calbiochem, San Diego,
CA), anti-Flag (M2), and anti-actin (AC40) (Sigma-Aldrich).
Horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences; eBioscience, San Diego, CA), alkaline
phosphatase (AP)-conjugated secondary antibodies (Santa
Cruz Biotechnology), and enhanced chemiluminescence (ECL)
reagents (Amersham Biosciences). All of the primary antibod-
ies were used according to the manufacturer’s instructions. All
reagents were from Sigma unless otherwise stated.
Comet Assay—The comet assay was performed as described
previously with some modifications (37). Cells were irradiated
with 10 Gy of IR, harvested at the indicated time points, and
mixed with low melting temperature agarose. After lysis, elec-
trophoresis was performed at 1 V/cm and 15 mA for 40 min.
Slides were stained with SYBG green dye for 10 min. Fifty ran-
domly selected cells per sample were captured under a Zeiss
fluorescent microscope, and digital fluorescent images were
obtained by using AxioVision software. The relative length and
intensity of SYBG green-stained DNA tails to heads was pro-
portional to the amount of DNAdamage present in the individ-
ual nuclei andwasmeasured byOlive tailmoment usingTriTek
Comet Score software (TriTek). The changes in percentage of
the relative comet tail moment between treatment (irradiation)
and control shown in all histograms represent the averages of
three independent experiments (n  50) (lower panel).
Pulse Chase Analysis—Cells were plated in 60-mm dishes.
One day later, the cells were incubated in Dulbecco’s modified
Eagle’s medium (no L-glutamine, sodium pyruvate, L-methio-
nine, or L-cystine) (Invitrogen, Cat. 21013-024) supplemented
with 5% dialyzed fetal bovine serum, 1 L-glutamine, 1
sodium pyruvate (Invitrogen), and 100 Ci of EXPRE35S35S
protein labeling mix (11 mCi/ml, PerkinElmer, Waltham, MA)
for 1–2 h. The medium was replaced with Dulbecco’s modified
Eagle’s medium containing 5% dialyzed fetal calf serum, 1
L-glutamine, 1 sodium pyruvate, 2 mM L-methionine, and 2
mM L-cystine (Sigma). At timed intervals during the chase
period, cells lysates were prepared in Nonidet P-40 lysis buffer
(50 mM Tris-HCl, pH 8, 150 mMNaCl, 0.5% Nonidet P-40, 10%
glycerol, 2 mM MgCl2, and1 mM EDTA) and immunoprecipi-
tated using the indicated antibodies. Immunocomplexes were
resolved by SDS-PAGE and analyzed by phosphorimage analy-
sis (GE Healthcare, Waukesha, WI).
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Quantitative Real-time PCR—Total RNA was isolated by
using TRIzol reagent (Invitrogen), and 2 g of total RNA was
reverse-transcribed using the SuperScript III First-strand syn-
thesis system for reverse transcriptase-PCR (RT-PCR) (Invitro-
gen). Quantitative real-time PCR (qPCR) was done by using
iQTM SYBR Green Supermix (Bio-Rad) on an iCycler iQ real-
time PCR detection system (Bio-Rad). The values for specific
genes were normalized to actin housekeeping controls. Primer
sequences are available in the supplemental Table S1. Ionizing
radiation (IR), in vivo ubiquitination assay, cycloheximide anal-
ysis, Western blot, and immunoprecipitation (IP) have been
described previously in detail (34).
RESULTS AND DISCUSSION
MTA1, a New Upstream Stabilizer of p53—To explore a
potential functional link between theMTA1 and p53 pathways,
we first examinedwhether these two proteins interact using the
wild-type p53-expressing human osteosarcoma U2OS cells (5)
or p53-null human lung cancerH1299 cells (4). Consistent with
previous studies (27, 31), we found an interaction between the
endogenous MTA1 and p53 in the U2OS cells but not in the
H1299 cells (negative control) (Fig. 1A). Furthermore, using
MTA1 knock-out (MTA1/) MEFs (35) as negative control,
we also confirmed the interaction between p53 and MTA1 in
the wild-type (MTA1/) but not in the MTA1/ MEFs (Fig.
1B). To determine whether MTA1 directly binds to p53, we
next performed in vitro GST pull-down assays using 35S-la-
beled, in vitro-translated MTA1 protein and full-length GST-
p53 fusion protein (38), and found that 35S-labeled MTA1
strongly bound to GST-p53 protein (supplemental Fig. S1A,
lane 4). To further identify the regions of p53 involved in bind-
ingMTA1,we used a series ofGST-p53 fusion proteins (38) and
analyzed their ability to bind to 35S-labeled, in vitro-translated,
full-length MTA1. We found that the observed MTA1 binding
to p53 was confined to amino acids 318–393 in the C terminus
(Fig. 1C and supplemental Fig. S1B). These findings in conjunc-
tion with other studies (27, 31) demonstrated thatMTA1 phys-
ically associates with p53 in vitro and in vivo.
Wenext examined the effect ofMTA1depletion on the levels
of endogenous p53. Interestingly, we discovered a marked
reduction in the level of p53 protein in the MTA1/ MEFs
relative to its level in the wild-type (MTA1/) controls (Fig.
2A). Furthermore, the noticed p53 reduction in the MTA1/
MEFs could be substantially reverted by reintroduction of
MTA1 in the MTA1/ MEFs (MTA1//MTA1) (Fig. 2B).
To assess whether the ability of MTA1 to affect p53 status in
cells is caused by a transcriptional effect or not, we found no
discernible difference in the level of p53 mRNA among the
MTA1/, MTA1/, andMTA1//MTA1MEFs as assayed
by qPCR (Fig. 2C), indicating a post-translational regulatory
role ofMTA1 in controlling the cellular level of p53 protein. To
validate these findings, we showed that selective siRNA-medi-
ated knockdown of the endogenous MTA1 in the U2OS cells
lead to a dose-dependent reduction in p53 protein (Fig. 2D).
Conversely, induced expression of MTA1 in the U2OS cells
(Fig. 2E) orwild-type humanp53 either alone orwith increasing
amounts of MTA1 in the p53-null H1299 cells (Fig. 2F)
increases the steady-state levels of p53. Collectively, these find-
FIGURE 1. MTA1 physically interacts with p53. A, protein extracts from the
wild-type p53-expressing U2OS or p53-null H1299 (negative control) cells
were immunoprecipitated with an anti-p53 antibody or IgG control, and
immunoblotted with the indicated antibodies. B, protein extracts from the
MTA1/ or MTA1/ (negative control) MEFs were immunoprecipitated
with an anti-MTA1 antibody and immunoblotted with the indicated antibod-
ies. C, diagrammatic summary of in vitro-translated MTA1 binding with a
series of GST-p53 constructs. Trans, transactivation domain; Pro, proline-rich
domain; DBD, DNA binding domain; Tetra, tetramerization domain; Reg, reg-
ulatory domain.
FIGURE 2. MTA1 is an upstream stabilizer of p53. A and B, protein extracts
from MTA1/ and MTA1/ MEFs (A) or from the MTA1/ and MTA1//
V5-MTA1 MEFs (B) were subjected to Western blot analysis with the indicated
antibodies. C, qPCR analysis of p53 mRNA levels in the MTA1/, MTA1/,
and MTA1//MTA1 MEFs. D and E, Western blot analysis of MTA1 and p53
protein expression in the U2OS cells transfected with increasing amounts of
specific siRNA targeting human MTA1 or control siRNA (D) or transfected with
increasing amounts of Myc-MTA1 expression plasmids (E). F, H1299 cells were
transfected with the pCMV-p53 plasmid either alone or in combination with
increasing amounts of Myc-MTA1, and the expression of MTA1 and p53 pro-
teins was detected by Western blot analysis.
MTA1 Coregulator Regulates p53 Stability and Function
DECEMBER 11, 2009 • VOLUME 284 • NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34547
ings suggest that MTA1 controls p53 protein expression
through a post-translational regulation mechanism.
Regulation of p53 Ubiquitination by MTA1—To further
confirm the above observations, we next tested whether
MTA1 affects the protein stability of p53 protein. As shown
in supplemental Fig. S2, induced expression of MTA1 in the
U2OS and H1299 cells in the presence of cycloheximide, an
inhibitor of protein biosynthesis, enhances the half-life of
p53 protein relative to the empty vector-transfected cells. To
further confirm these findings, we performed the classic
pulse chase experiments using metabolic labeling of cells
with [35S]methionine. In agreement with the above observa-
tions, we found that MTA1 expression increases the half-life
of both endogenous and exogenously transfected p53 pro-
tein in the wild-type p53-expressing U2OS (Fig. 3A) and
p53-null H1299 (Fig. 3B) cells, respectively. To examine
whether p53 half-life is critically regulated by endogenous
MTA1 levels, we performed the metabolic labeling experi-
ments as described above using the MTA1/ and
MTA1/ MEFs. As shown in Fig. 3C, knock-out of MTA1
causes a marked decrease in the half-life of p53 protein. Col-
lectively, these results suggest that MTA1 controls the sta-
bility of p53 protein and conse-
quently may constitute a new
upstream regulator of p53 protein.
Regulation of p53 stability is
achieved through a series of post-
translational modifications, includ-
ing ubiquitination (39). To test
whether MTA1 stabilizes p53 by
inhibiting its ubiquitination, we
examined the effect of MTA1 on
the levels of endogenous p53 ubiq-
uitination in the MCF-7/pcDNA
and MCF-7/T7-MTA1 stable clone
cells (36). As shown in Fig. 3D, over-
expression of MTA1 in the MCF-7
cells was accompanied by a de-
creased endogenous p53 ubiquitina-
tion and increased p53 protein. Simi-
larly, Myc-MTA1 expression in HEK
293 cells also suppressed the level
of p53 ubiquitination (Fig. 3E). To
document the specificity of the
noticed inhibitory effect of MTA1
on p53 ubiquitination, we showed
that there was no inhibitory effect
ofMTA2 orMTA3 on p53 ubiquiti-
nation inHEK293 cells (supplemen-
tal Fig. S3). These findings suggest
that MTA1 stabilizes p53 protein
by, at least in part, inhibiting its
ubiquitination.
MTA1 Inhibits the COP1-medi-
ated p53 Ubiquitination and Deg-
radation—The p53 ubiquitination
is primarily mediated by RING fin-
ger E3 ubiquitin ligases COP1 (3),
Mdm2 (4, 5), and Pirh2 (6), leading to its proteasomal degrada-
tion.We next examined the effect of MTA1 on p53 ubiquitina-
tion mediated by these E3 ligases in HEK293 cells. We found
that forced expression of MTA1 markedly abrogates p53 ubiq-
uitination induced by COP1 (Fig. 4A, compare lane 5with lane
4). In contrast, MTA1 expression only marginally inhibited the
Pirh2-mediated p53 ubiquitination (supplemental Fig. S4).
Given the fact that COP1 is a critical negative regulator of p53
(3) and emerging evidence that MTA1 promotes COP1 degra-
dation by enhancing its auto-ubiquitination (34), we next tested
whether MTA1 could protect p53 from degradation by COP1.
To this end, the p53//Mdm2/double-nullMEFs (40)were
transfected with pCMV-p53 either alone or in combination
with a constant amount of T7-COP1, or with increasing
amounts of Myc-MTA1. We found that COP1 expression in
this experimental system leads to p53 degradation as expected
(3). However, coexpression of MTA1 efficiently restored the
levels of p53 by preventing its degradation by COP1 (Fig. 4B),
presumably because of down-regulation of COP1 by
MTA1(34), and thereby, rescuing p53 from COP1-mediated
degradation. To further confirm this notion, we next examined
the impact of MTA1 on COP1 stability by pulse chase analysis
FIGURE 3. MTA1 regulates p53 protein stability by inhibiting its ubiquitination. A and B, U2OS (A) or H1299
(B) cells were transfected with the indicated expression vectors. After 36 h of transfection, cells were labeled
using [35S]methionine and subjected to pulse chase analysis. Cells were harvested at various time points during
the chase period and immunoprecipitated using an anti-p53 antibody. Complexes were resolved by SDS-PAGE
and exposed to storage phosphor screens. The intensity of the labeled p53 band was quantified by phosphor-
image analysis using ImageQuant software (Molecular Dynamics), and the percent p53 remaining was calcu-
lated relative to that at the beginning of the chase period (time 0). The mean values from three independent
experiments are shown. C, MTA1/ and MTA1/ MEFs were labeled using [35S]methionine and subjected to
pulse chase analysis as described above. D, protein extracts from the MCF-7/pcDNA and MCF-7/T7-MTA1 cells
were subjected to IP with an anti-p53 antibody, following by Western blot analysis with the indicated antibod-
ies. E, HEK293 cells were transfected with the indicated plasmids and subjected to the sequential IP/Western
blot analysis as described above.
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and found that induced expression of MTA1 in U2OS cells
decreases the half-life of endogenous COP1 (Fig. 4C). In sup-
port of these findings, knock-out of MTA1 increases the half-
life of endogenous COP1 (Fig. 4D). These results suggest that
MTA1 inhibits the COP1-mediated p53 ubiquitination and
degradation through, at least in part, destabilizing COP1.
Because both COP1 (3) and MTA1 (Fig. 1C) (27) could
directly interact with p53, we next explored an additional
mechanistic possibility thatMTA1andCOP1may compete for
binding to p53. In this context, because the exact p53 binding
region for COP1 remains unknown, we first mapped the
regions of p53 involved in binding COP1 using a series of GST-
p53 fusion proteins (38). Results showed that 35S-labeled, in
vitro-translated COP1 binds to the DNA binding domain
(amino acids 92–160) and the C-terminal domain (amino acids
318–393) of p53 (Fig. 4E and supplemental Fig. S5). Because
both MTA1 (Fig. 1C) and COP1 (Fig. 4E) proteins bind the
amino-acids 318–393 in the C terminus of p53, it raised the
possibility of competition of two proteins to a common p53
binding region. Indeed, we found that MTA1 and COP1 could
interact with p53 and co-incubation of both MTA1 and COP1
blocks COP1 binding to p53 (Fig. 4F). In brief, MTA1 overex-
pression may inhibit the COP1-mediated p53 degradation by
destabilizing COP1 (34) or by competing with COP1 to bind to
p53 or by both mechanisms.
MTA1 Inhibits the Mdm2-mediated p53 Degradation—In
addition to COP1, Mdm2 is another critical cellular antagonist
of p53 (4, 5). Similar toCOP1,we found thatMTA1also inhibits
the Mdm2-mediated ubiquitination of p53 (Fig. 5A). To deter-
mine whetherMTA1 could protect p53 from theMdm2-medi-
ated degradation, the p53//Mdm2/ MEFs were trans-
fected with pCMV-p53 either alone or in combination with a
constant amount of pCMV-Mdm2, and increasing amounts of
Myc-MTA1. Consistent with previous reports (4, 5), Mdm2
overexpression decreases the level of p53.However, concurrent
expression of MTA1 was accompanied by a reduced level of
Mdm2 and in turn, increased amount of its target p53 (Fig. 5B).
To identify the underlying mechanism of this event, we found
that MTA1 overexpression led to a reduction in the level of the
exogenously expressed Flag-Mdm2 in the p53//Mdm2/
MEFs (Fig. 5C). To test whether MTA1 expression affects the
stability of Mdm2 protein, we measured the half-life of Mdm2
in theMCF-7/pcDNAandMCF-7/T7-MTA1 cells (36). Results
indicated that the half-life of Mdm2 is substantially longer in
theMCF7/pcDNA cells than that in theMCF7/T7-MTA1 cells
(Fig. 5D), suggesting a destabilizing effect of MTA1 on Mdm2.
To further confirm these findings, we performed the classic
pulse chase experiments using metabolic labeling of cells with
[35S]methionine. In line with the above observations, we found
that induced expression of MTA1 in U2OS cells decreases the
half-life of Mdm2 (Fig. 5E). In contrast, knock-out of MTA1
increases the half-life of endogenousMdm2 (Fig. 5F). Although
MTA1 expression promoted Mdm2 degradation (Fig. 5, B and
C), paradoxically, it did not promoteMdm2 self-ubiquitination
(supplemental Fig. S6) as was the case with COP1 (34). These
findings are consistent with the recently emerging notion that
the Mdm2 E3 function is not required for its self-degradation
(41), the significance of which continues to be an important
FIGURE 4. MTA1 inhibits the COP1-mediated p53 ubiquitination and deg-
radation. A, HEK293 cells were transfected with the indicated plasmids. After
36 h of transfection, total cell lysates were prepared and subjected to
the sequential IP/Western blot analysis with the indicated antibodies.
B, p53//Mdm2/ double-null MEFs were transfected with the indicated
expression vectors and immunoblotted with the indicated antibodies. C and
D, U2OS cells transfected the indicated expression vectors (C) or MTA1/
and MTA1/ MEFs (D) were labeled using [35S]methionine and subjected to
pulse chase analysis as described above except that immunoprecipitations
were carried out using an anti-COP1 antibody. E, schematic representation of
the domains of p53 protein for COP1 binding. Trans, transactivation domain;
Pro, proline-rich domain; DBD, DNA binding domain; Tetra, tetramerization
domain; Reg, regulatory domain. F, in vitro competition binding assay of
MTA1 and COP1 to p53. In vitro-translated 35S-labeled MTA1 or COP1 protein
was incubated with GST or GST-p53-fused protein. Bound proteins were sep-
arated and analyzed by SDS-PAGE and autoradiography.
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research question. Because Mdm2 (38) and MTA1 (Fig. 1C)
bind to the different domains of p53, no binding competition is
expected between these proteins for p53 binding aswas the case
for COP1 (Fig. 4F). In brief, MTA1 stabilizes p53 levels by
down-regulating Mdm2 and thereby, preventing the ability of
Mdm2 to ubiquitinate its substrate p53.
We next determined whether MTA1 could interact with
Mdm2. We found that Myc-MTA1 specifically coimmunopre-
cipitates Flag-Mdm2 in HEK293 cells (Fig. 6A, left panel).
Moreover, we also observed this interaction in a reverse exper-
iment using an anti-Flag antibody for IP (Fig. 6A, right panel).
More importantly, we also found evidence of a physical inter-
action between the endogenousMTA1 andMdm2 in theU2OS
and the MCF-7 cells by reciprocal IP using an anti-Mdm2 or
anti-MTA1 antibody (Fig. 6B). To support these findings, in
vitro GST pull-down assays revealed that indeed, recombinant
MTA1 directly interacts with the N terminus of Mdm2 (amino
acids 1–110) (Fig. 6C and supplemental Fig. S7). Collectively,
these findings along with from the preceding sections suggest
that MTA1 stabilizes the level of p53 via, at least in part, inhib-
iting its ubiquitination by COP1 and Mdm2.
MTA1 Deficiency Impairs p53-dependent p53R2 Transcrip-
tion and DNA Repair—The p53 tumor suppressor is a
sequence-specific transcriptional factor that is rapidly stabi-
lized and activated in response to a variety of genotoxic stresses,
resulting in a controlled activation of a series of downstream
target genes involved in its functions (2, 10, 11, 42). p53R2, a
recently identified ribonucleotide reductase, is directly induced
by p53 in response to various genotoxic stresses, for supplying
nucleotides to repair damagedDNA (20, 21). Thus, inactivation
of p53 could directly interfere with damage-induced transcrip-
tion of p53R2 (20). Given the fact that p53R2 expression is asso-
ciated with p53 status and thatMTA1 controls the steady-state
levels of p53 protein (Fig. 2), we next examined whetherMTA1
expression affects the p53-dependent p53R2 transcription. We
found that the p53 reduction in the MTA1/ MEFs was
accompanied by a corresponding reduction in the level of
p53R2mRNA, compared with its level inMTA1/ MEFs (Fig.
FIGURE 5. MTA1 inhibits the Mdm2-mediated degradation of p53.
A, HEK293 cells were transfected with the indicated plasmids and subjected
to the sequential IP/Western blot analysis as described above. B and C, p53//
Mdm2/ double-null MEFs were transfected with the indicated expression
vectors and immunoblotted with the indicated antibodies. D, MCF-7/pcDNA
and MCF-7/T7-MTA1 cells were treated with 100 g/ml of cycloheximide and
harvested at indicated times for Western blot analysis with the indicated anti-
bodies (upper panel). Western blots were subjected to densitometric analysis
and results were normalized based on actin expression levels and reported in
graphical form (lower panel). E and F, U2OS cells transfected the indicated
expression vectors (E) or MTA1/ and MTA1/ MEFs (F) were labeled using
[35S]methionine and subjected to pulse chase analysis as described above
except that immunoprecipitations were carried out using an anti-Mdm2
antibody.
FIGURE 6. MTA1 physically interacts with Mdm2. A, HEK293 cells were
transfected with expression vectors encoding Myc-MTA1 and Flag-Mdm2
and immunoprecipitated with IgG control or specific antibody against Myc or
Flag, followed by immunoblotting with the indicated antibodies. B, protein
extracts from the U2OS and MCF-7 cells were subjected to IP with anti-Mdm2
or anti-MTA1 antibody or IgG control, followed by Western blot analyses with
the indicated antibodies. C, diagrammatic summary of in vitro-translated
MTA1 binding with a series of GST-Mdm2 protein.
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7A). Moreover, the reduction of p53R2 mRNA levels in the
MTA1/ MEFs could be partially reverted by the reintroduc-
tion of MTA1 in the MTA1/ MEFs (Fig. 7A); these changes
parallel the observed p53 levels in these cells (Fig. 2,A andB). In
contrast to p53R2, there was no significant change in the
mRNA level of Bax gene, another p53 primary-response gene
(43) (Fig. 7B). Although exposure of theMTA1/, MTA1/,
and MTA1//MTA1 MEFs to IR rapidly induced p53R2
mRNA expression in all three cell types, the maximum induci-
ble level of p53R2 remained significantly lower in the
MTA1/ MEFs than that in the MTA1/ and MTA1//
MTA1 MEFs (Fig. 7C), supporting the idea that MTA1 regu-
lates the p53-dependent p53R2 transcription.
Inhibition of endogenous p53R2 expression in cells with an
intact p53-dependent DNA damage checkpoint reduces the
ability of cell to repair DNA damage and leads to increased
sensitivity to genotoxic stress (20, 22, 23). Aswe discovered that
MTA1 is necessary for an efficient induction of p53 target
p53R2 (Fig. 7, A and C), we next evaluated whether the DNA
repair capacity was compromised in theMTA1/ cells by per-
forming single cell electrophoresis analysis under the neutral
conditions (neutral comet assay) that specifically measures
DNADSBs in cells damaged by IR at the level of individual cells
(37, 44). Results showed that, immediately after irradiation (0 h)
by 10 Gy of IR, approximately the same amounts of DNA frag-
ments were generated from the MTA1/, MTA1/, and
MTA1//MTA1 MEFs (Fig. 7D). When remaining unre-
paired DNA fragments were monitored at various hours after
IR treatment, we found that MTA1/ MEFs exhibited the
much higher levels of damaged DNA than the MTA1/ and
MTA1//MTA1 MEFs (Fig. 7D), suggesting that MTA1 is
required for efficient DBS repair.
In summary, findings presented here establish that MTA1
controls p53 stability and consequently regulates p53-depen-
dent transcription of p53R2, a gene responsive for supplying
nucleotides for DNA repair following DNA damage (Fig. 8).
This newly revealed function of MTA1 is mechanistically
linked with its (but notMTA2 andMTA3) ability to inhibit p53
ubiquitination by destabilizingCOP1 andMdm2or by compet-
ing with COP1 to bind to p53 protein (Fig. 8). Of interest, there
was no compensatory effect ofMTA1 depletion inMEFs on the
levels of MTA2 (Fig. 2A), which as a part of the NuRD complex
has been previously shown to deacetylate p53 and inhibits p53-
dependent transcription of genes important in cell growth and
apoptosis (26), whereas the role in DNA damage response was
not investigated in that study.We found thatMTA1 is required
for the p53-dependent DNA repair and that inactivation of
MTA1 increases the cellular sensitivity to IR-induced DNA
damage (Fig. 7D). Because MTA1 is widely up-regulated in
human cancers, findings presented here in conjunction with
our earlier finding of a crucial role of MTA1 in DSB repair
suggest an inherent role ofMTA1-p53-p53R2 pathway in DNA
damage response in cancer cells.
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